For research use only. Not for therapeutic Use.
Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia[1][2].
| Catalog Number | I042207 |
| CAS Number | 1610833-03-8 |
| Purity | ≥95% |
| Reference | [1]. Schindeler A, et al. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children. Front Endocrinol (Lausanne). 2020 May 28;11:338. [2]. Colangelo L, et al. Appropriate dosing of burosumab in tumor-induced osteomalacia. Osteoporos Int. 2022 Dec 1. |
